Antonia S, et al. Overall survival with durvalumab versus placebo after chemoradiotherapy in stage III NSCLC: updated results from PACIFIC. IASLC 2018, abstract PL02.01.
Profiteren van resistentieontwikkeling bij tumorcellen
mei 2018 | Dermato-oncologie